BRIEF-TG Therapeutics Announces Publication Of Final Results From The Phase 3 Genuine Trial Evaluating Ublituximab Plus Ibrutinib In Patients With Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia In The Lancet Haematology

Reuters · Feb 23, 2021 20:32

Feb 23 (Reuters) - TG Therapeutics Inc TGTX.O :

* TG THERAPEUTICS ANNOUNCES PUBLICATION OF FINAL RESULTS FROM THE PHASE 3 GENUINE TRIAL EVALUATING UBLITUXIMAB PLUS IBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA IN THE LANCET HAEMATOLOGY

Source text for Eikon: Further company coverage:

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

BRIEF-TG Therapeutics Announces Publication Of Final Results From The Phase 3 Genuine Trial Evaluating Ublituximab Plus Ibrutinib In Patients With Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia In The Lancet Haematology

Risk Disclaimer